|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | What we should know about portal vein thrombosis in cirrhotic patients:A changing perspective显示文摘Portal vein thrombosis(PVT) is one of the most common complications occurring during the natural course of liver cirrhosis.Even though PVT is often asymptomatic,the worsening of liver function,an unexpected episode of gastrointestinal bleeding or ascitic decompensation may be landmarks of PVT development.Beyond these clinical manifestations,it is debated whether PVT really has an impact on liver cirrhosis natural history or rather represents only one of its consequences.Probably PVT development should not only be considered as a matter of impaired blood flow or pro-coagulation tendency.On one hand,PVT seems a consequence of the worsening in portal vein outflow due to the increased hepatic resistance in cirrhotic livers.On the other hand,vascular microthrombosis secondary to necroinflammation may cause liver ischemia and infarction,with loss of hepatic tissue(parenchymal extinction) which is replaced by fibrotic tissue.Therefore,PVT might also be considered as the overt manifestation of the liver fibrosing process evolution and anticoagulant therapy may thus have microscopic indirect effects also on the progression of liver disease.At present,a connection between PVT development and the progression of liver fibrosis/cirrhosis has not yet been demonstrated.Nevertheless,it is not clear if PVT development may worsen cirrhotic patients' outcome by itself.Some authors tried to assess liver transplant benefit in PVT cirrhotic patients but data are contrasting.In this review,we will try to answer these questions,providing a critical analysis of data reported in literature. | Francesca Romana Ponziani Maria Assunta Zocco Matteo Garcovich Francesca D'Aversa Davide Roccarina Antonio Gasbarrini | 2012 | World Journal of Gastroenterology2012，18，36： | 24 |
| 2 | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation显示文摘Antibiotics are usually prescribed to cure infections but they also have significant modulatory effects on the gut microbiota. Several alterations of the intestinal bacterial community have been reported during antibiotic treatment, including the reduction of beneficial bacteria as well as of microbial alpha-diversity. Although after the discontinuation of antibiotic therapies it has been observed a trend towards the restoration of the original condition, the new steady state is different from the previous one, as if antibiotics induced some kind of irreversible perturbation of the gut microbial community. The poorly absorbed antibiotic rifaximin seem to be different from the other antibiotics, because it exerts non-traditional effects additional to the bactericidal/bacteriostatic activity on the gut microbiota. Rifaximin is able to reduce bacterial virulence and translocation, has anti-inflammatory properties and has been demonstrated to positively modulate the gut microbial composition. Animal models, culture studies and metagenomic analyses have demonstrated an increase in Bifidobacterium, Faecalibacterium prausnitzii and Lactobacillus abundance after rifaximin treatment, probably consequent to the induction of bacterial resistance, with no major change in the overall gut microbiota composition. Antibiotics are therefore modulators of the symbiotic relationship between the host and the gut microbiota. Specific antibiotics, such as rifaximin, can also induce eubiotic changes in the intestinal ecosystem; this additional property may represent a therapeutic advantage in specific clinical settings. | Francesca Romana Ponziani Maria Assunta Zocco Francesca D’Aversa Maurizio Pompili Antonio Gasbarrini | 2017 | World Journal of Gastroenterology2017，23，25： | 17 |
| 3 | Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications显示文摘Liver cirrhosis is a paradigm of intestinal dysbiosis. The qualitative and quantitative derangement of intestinal microbial community reported in cirrhotic patients seems to be strictly related with the impairment of liver function. A kind of gut microbial 'fingerprint',characterized by the reduced ratio of 'good' to 'potentially pathogenic' bacteria has recently been outlined,and is associated with the increase in Model for End-Stage Liver Disease and Child Pugh scores. Moreover,in patients presenting with cirrhosis complications such as spontaneous bacterial peritonitis(SBP),hepatic encephalopathy(HE),and,portal hypertension intestinal microbiota modifications or the isolation of bacteria deriving from the gut are commonly reported. Rifaximin is a non-absorbable antibiotic used in the management of several gastrointestinal diseases. Beyond bactericidal/bacteriostatic,immune-modulating and anti-inflammatory activity,a little is known about its interaction with gut microbial environment. Rifaximin has been demonstrated to exert beneficial effects on cognitive function in patients with HE,and also to prevent the development of SBP,to reduce endotoxemia and to improve hemodynamics in cirrhotics. These results are linked to a shift in gut microbes functionality,triggering the production of favorable metabolites. The low incidence of drug-related adverse events due to the small amount of circulating drug makes rifaximin a relatively safe antibiotic for the modulation of gut microbiota in advanced liver disease. | Francesca Romana Ponziani Viviana Gerardi Silvia Pecere Francesca D'Aversa Loris Lopetuso Maria Assunta Zocco Maurizio Pompili | 2015 | World Journal of Gastroenterology2015，21，43： | 16 |
| 4 | Optimal management of a patient with recurrent nasopharyngeal carcinoma显示文摘Nasopharyngeal carcinoma is rare in western countries, accounting for less than 1% of all malignancies. Despite prognosis is satisfactory for newly diagnosed, non-metastatic disease, management of recurrent disease is challenging, with a survival expectancy of approximately 6 mo with the use of chemotherapy as the sole salvage treatment. We report a case of recurrent nasopharyngeal carcinoma treated with a combination of chemotherapy, radiotherapy and surgery in the context of a multidisciplinary approach. A durable complete response was achieved. | Francesco Perri Italo Dell’Oca Paolo Muto Concetta Schiavone Corrado Aversa Franco Fulciniti Raffaele Solla Giuseppina Della Vittoria Scarpati Carlo Buonerba Giuseppe Di Lorenzo Francesco Caponigro | 2014 | World Journal of Clinical Cases2014，2，7： | 8 |
| 5 | New oral agents for erectile dysfunction: what is changing in our practice?显示文摘Erectile dysfunction (ED) is a highly prevalent disorder affecting an estimated 152 million men worldwide and is associated with a variety of behavioral risk factors, such as cigarette smoking and excessive alcohol consumption, as well as numerous age-related medical conditions, notably type-2 diabetes mellitus and cardiovascular disease. A rational step-wise approach which includes comprehensive medical and sexual history, a focused physical examination and essential laboratory tests such as fasting glucose, lipid profile and testosterone assay is to be preferred. Current diagnostic work-up does not recommend any of the specialized tests which were previously considered mandatory-i. e. penile pharmacotesting, Duplex ultrasound and nocturnal penile tumescence. Hormonal replacement therapy is appropriate only in the hypogonadal male with ED. Prior to direct intervention, the physician should consider altering modifiable risk factors or causes, although frequently insufficient to reverse ED completely. When indicated, oral therapy with new molecules (phosphodiesterase inhibitors or apomorphine) is the first-line treatment for the majority of patients because of potential benefits and lack of invasiveness. | Antonio Aversa Andrea Fabbri | 2001 | Asian Journal of Andrology2001，3，3： | 4 |
| 6 | Full haplotype-mismatched hematopoietic stem-cell transplantation:a phase Ⅱ study in patients with acute leukemia at high risk of relapse 显示文摘 | Aversa F Terenzi A Tabilio A | 2005 | J Clin Oncol2005，23，15： | 1 |
| 7 | Three-dimensional finite element analysis of strain and stress distributions in endo donitically treated maxillary central incisors restored with different post,core and crown moterials显示文摘 | Sorrentino R Aversa R Ferro V | 2007 | Dent Mater2007，23，8： | 1 |
| 8 | A survey of fully haploidentical hematopoietic stem cell transplanta- tion in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at trans- plantation显示文摘 | CICERI F LABOPIN M AVERSA F | 2008 | Blood2008，112，： | 1 |
| 9 | Transplants across human leukocyte antigen barriers显示文摘 | Martelli M F Aversa F Bachar-Lustig E | 2002 | Semin Hematol2002，39，1： | 1 |
| 10 | Cervical spondylotic myelopathy: 10 years of prospective outcome analysis of anterior decompression and fusion 显示文摘 | Chagas H Domigues F Aversa A | 2005 | Surg Neurol2005，641，： | 1 |
| 11 | Treatment of high - risk acute leukemia with T - cell - depleted stem cells from re- lated donors with one fully mismatched HLA haplotype显示文摘 | AVERSA F TABILIO A VELARDI A | 1998 | N En- gl J Med1998，339，17： | 1 |
| 12 | Gut microbiota and metabolic syndrome显示文摘 | Francesca D’Aversa Annalisa Tortora Gianluca Ianiro Francesca Romana Ponziani Brigida Eleonora Annicchiarico Antonio Gasbarrini | 2013 | Internal and Emergency Medicine2013，，1： | 1 |
| 13 | Phase Ⅱ randomized study of dacarbazine,carmustine,cisplatin and tamoxifen versus dacarbazine alone in advanced melanoma patients 显示文摘 | Chiarion Sileni V Nortilli R Aversa SM | 2001 | Melanoma Res2001，11，2： | 1 |
| 14 | Haploidentical stem cell transplantation for acute leukemia显示文摘 | Aversa F Terenzi A Felicini R | 2002 | Int J Hematol2002，76，1： | 1 |
| 15 | Galectin-3:presurgical marker of thyroid follicular epithelial cell-derived carcinomas显示文摘 | Saggiorato E Aversa S Deandreis D | 2004 | J Endocrinol2004，27，4： | 1 |
| 16 | Hematopoietic stem cell transplantation from alternative donors for high - risk a- cute leukemia: the haploidentical option显示文摘 | AVERSA F TABILIO A VELARDI A | 2007 | Curr Stem Cell Res Ther2007，2，1： | 1 |
| 17 | Treatment of highrisk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype 显示文摘 | Aversa F Tabilio A Velardi A | 1998 | N Engl J Med1998，339，： | 1 |
| 18 | Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells显示文摘 | Punnonen J Aversa G Benjamin G C | 1993 | Proc Natl Acad Sci1993，90，： | 1 |
| 19 | Occlusion and temporomandibular disorders:a malpractice case with medical legal considerations显示文摘 | Bucci MB Aversa M Guarda-Nardini L | 2011 | Minerva Stomatol2011，60，12： | 1 |
| 20 | Haploidentical haematopoietic stem ceil transplanta- tion for acute leukaemia in adults: experience in Europe and the United States 显示文摘 | AVERSA F | 2008 | Bone Marrow Transplant2008，41，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员